ArticleFrontiers in immunology2026
Short-term quantitative CT changes in synchronous ground-glass nodules during immune checkpoint inhibitor therapy in patients with lung cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have improved survival in patients with lung cancer, leading to more frequent detection of synchronous ground-glass nodules (GGNs) during follow-up. This study aimed to evaluate short-term longitudinal quantitative CT changes of synchronous GGNs in lung cancer patients receiving ICI therapy. Methods: In this retrospective matched cohort study, we included 90 patients with lung cancers harboring 110 synchronous GGNs receiving 3-4 cycles of ICIs, and compared them with a matched cohort of incidentally detected pulmonary GGNs without any therapy. Baseline and follow-up chest CT scans were quantitatively analyzed to capture changes of diameter, volume, surface area, mass, mean CT attenuation, standard deviation of CT attenuation, solid component proportion, sphericity, energy and entropy. Volume change proportion (VCP) was assessed to define nodule response, using ± 25% as the threshold. Subgroup analyses were conducted according to nodule density and Lung-RADS category. Results: VCP showed that nodules in ICI group were more likely to show regression than those in the control group (23.6% Conclusion: Among lung cancer patients receiving ICIs, synchronous GGNs exhibited attenuated longitudinal CT growth patterns, with favorable shifts in VCP and Lung-RADS categories, particularly in PSNs and nodules with Lung-RADS ≥ 4A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.